Exthera Medical Corporation

Dsm IP Assets B.v.

Thoratec Laboratories Corporation

The Polymer Technology Group, Incorporated

Th. Goldschmidt Ag

Biomimedica, Inc.

Emergence Venture Partners, LLC

Johnson and Johnson Vision Care, Inc.

Isense Corporation

Dsm Biomedical Inc.

Robert S Ward

Keith R McCrea

Olle Larm

Lars Adolfsson

Judy Smith Riffle

Yuan Tian

James Parakka

Keith R Mccrea

Shanger Wang

Keith Mccrea

Kathleen A White

David Myung

Lampros Kourtis

Xuwei Jiang

Michael J Jaasma

Patrick F Kiser

Meredith Roberts Clark

Li Li

Durgaprasad Chalasani

Jonas Axelsson

Sallie K Coviello

Robert L Jones

Shivkumar Mahadevan

W Kenneth Ward

Frank Molock

Ellen M Anderson

Tomas Bergstrom

Tomas Bergström

Ananth V Iyer

Scott Curtin

Donald R Beckham

Lakhmir (Mink) Chawla

Keith McCrae

George Pitarra, Jr

Anfeng Wang

Jody House

James M Serpilio, Jr

Keith McCREA

James P Parakka

Thomas Bergstrom

Thomas Bergström

The present invention provides methods and devices for augmenting impaired glycocalyx barrier function in a subject in need thereof by contacting a sample (e.g., blood) obtained from the subject with a glycocalyx-mimetic adsorption media. The adsorption media includes glycosaminoglycan structures and, optionally, proteoglycan core proteins, which are conducive to enhancing and/or restoring the impaired glycocalyx barrier function in a sample. The contacted sample is subsequently separated from the adsorption media, producing a treated sample that can be infused into the subject. Methods and devices for treating a patient suffering from a disease associated with glycocalyx barrier dysfunction are also provided herein.

Method for modulating endothelial glycocalyx structure

Methods and devices are disclosed for the treatment of a subject suffering from drug intoxication by cleansing a contaminated sample from the subject with adsorption media. The adsorption media composition is selected for its antithrombogenic properties and for its ability to adhere to one or more drug targets to be reduced or eliminated. The media can further be held in a cartridge for use in extracorporeal treatments such as those of hemoperfusion. Contacting the contaminated sample from the subject with the absorption medium allows for the separation of a portion of the drug target from the sample, producing a cleansed sample that can be infused into the subject.

Method for treating drug intoxication

The present invention provides methods for removing a significant amount of bacteria (e.g., gram-negative bacteria and gram-positive bacteria, including bacteria with no or low affinity for heparan sulfate) from whole blood, serum or plasma using an adsorption media. The method can be used in extracorporeal treatments involving high volumetric flow rates and high linear flow rates.

Method for removing bacteria from blood using high flow rate

The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods.

Methods for diagnosing infectious diseases using adsorption media

The method is described as the removal of mediators that contribute to the pathogenesis of cancer from blood by contacting the blood with a solid, essentially non-micro-porous substrate which has been surface treated with heparin, heparan sulfate and, optionally, other molecules or chemical groups (the adsorbent media or media) having a binding affinity to the mediator, and wherein the size of the interstitial channels within said substrate are balanced with the amount of interstitial substrate surface area such that high flow rates of blood past said substrate creates a flow transport that is characterized by convection transport more than Brownian diffusion transport.

Use of heparin and carbohydrates to treat cancer

The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

Methods for removing cytokines from blood with surface immobilized polysaccharides

The present technology relates to methods and devices for the removal of toxins and pathogens from infected blood of patients. In particular, devices are designed to be portable, wearable, disposable and self-contained extracorporeal devices that can be easily assembled from a kit.

Wearable hemoperfusion device

A blood filtration method, system, device and media for removing gram negative bacteria from the blood wherein the media includes a substrate coated with mannose optionally in constitution with substrate coated with heparin.

Blood filtration system containing mannose coated substrate

The present invention is directed to an integrated system and a method for utilizing the system to detect and remove blood-borne factors of interest, such as pathogens and/or toxins and/or cytokines, from blood or serum (blood) by contacting the blood with a solid, essentially nonporous substrate which has been surface treated with molecules or chemical groups (the adsorbent media or media) having a binding affinity for the pathogens and/or toxins to be removed (the adsorbents). The invention can be used to remove virulence factors, e.g. toxins, that are released from various pathogens. In one aspect, the invention is for the treatment of sepsis and infection, such as infections associated with battle field trauma.

Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines

The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood com-Components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.

Device and method for restoration of the condition of blood

Intravaginal drug delivery device comprising at least one pharmaceutically active substance, and a polyurethane copolymer, wherein the copolymer has the structure according to formula (I): Also, method comprising administering one or more pharmaceutically active substances to a patient in need thereof.

Intravaginal ring comprising polyurethane composition for drug delivery

Growing community of inventors

Lafayette, CA, United States of America

Robert S Ward